Literature DB >> 9529155

Defective NK cell activity and Th1 response in IL-18-deficient mice.

K Takeda1, H Tsutsui, T Yoshimoto, O Adachi, N Yoshida, T Kishimoto, H Okamura, K Nakanishi, S Akira.   

Abstract

IL-18 is a cytokine that is secreted from activated macrophages and induces IFNgamma production. To investigate the in vivo role of IL-18, we generated IL-18-deficient mice. In Propionibacterium acnes (P. acnes)-primed IL-18-deficient mice, LPS-induced IFNgamma production was markedly reduced, despite normal IL-12 induction. Natural killer cell activity was significantly impaired. Th1 cell response after injection of P. acnes or Mycobacterium bovis (bacillus Calmette-Guerin [BCG]) was significantly reduced. Similar results were observed in IL-12-deficient mice. Interestingly, Th1 response was induced after BCG infection in IL-12-deficient mice. We therefore generated mice lacking both IL-18 and IL-12. In these mice, NK activity and Th1 response were further impaired. This demonstrates the important role of both IL-18 and IL-12 in NK activity, as well as in in vivo Th1 response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9529155     DOI: 10.1016/s1074-7613(00)80543-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  256 in total

Review 1.  Molecular mechanisms in T helper phenotype development.

Authors:  J D Farrar; S H Ranganath; K M Murphy
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Clonal expansion of antigen-specific CD4 T cells following infection with Salmonella typhimurium is similar in susceptible (Itys) and resistant (Ityr) BALB/c mice.

Authors:  Z M Chen; M K Jenkins
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

3.  Role of endogenous interleukin-12 in immune response to staphylococcal enterotoxin B in mice.

Authors:  F N Lauw; S Florquin; P Speelman; S J van Deventer; T van der Poll
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

4.  Interleukin-12 (IL-12) and IL-18 are important in innate defense against genital herpes simplex virus type 2 infection in mice but are not required for the development of acquired gamma interferon-mediated protective immunity.

Authors:  A M Harandi; B Svennerholm; J Holmgren; K Eriksson
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice.

Authors:  I Sugawara; H Yamada; H Kaneko; S Mizuno; K Takeda; S Akira
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

6.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18.

Authors:  S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

7.  Relationship between plasma Interleukin-12 (IL-12) and IL-18 levels and severe malarial anemia in an area of holoendemicity in western Kenya.

Authors:  Sujittra Chaisavaneeyakorn; Caroline Othoro; Ya Ping Shi; Juliana Otieno; Sansanee C Chaiyaroj; Altaf A Lal; Venkatachalam Udhayakumar
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

8.  T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-gamma and IL-13 production.

Authors:  Nobuki Hayashi; Tomohiro Yoshimoto; Kenji Izuhara; Kiyoshi Matsui; Toshio Tanaka; Kenji Nakanishi
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-31       Impact factor: 11.205

9.  T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm.

Authors:  Uwe Schönbeck; Galina K Sukhova; Norbert Gerdes; Peter Libby
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

10.  Interleukin-18 controls energy homeostasis by suppressing appetite and feed efficiency.

Authors:  Eric P Zorrilla; Manuel Sanchez-Alavez; Shuei Sugama; Molly Brennan; Rosette Fernandez; Tamas Bartfai; Bruno Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.